Pfizer Inc vs uniQure N.V. Ordinary Shares — how do they compare? Pfizer Inc trades at $29.5 (market cap $161.70B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Pfizer Inc is far larger — about 109.3× uniQure N.V. Ordinary Shares's market cap, and Pfizer Inc pays a 6.06% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| PFE | QURE | |
|---|---|---|
Market Cap | $161.70B | $1.48B |
Volume | 26,828,084 | 2,488,780 |
Sector | Health | Health |
52-Week High | $29.21 | $70.59 |
52-Week Low | $23.67 | $9.03 |
Typical Hold Time | 158 Days | 0 Days |
Enterprise Value | $213.20B | $728.62M |
Dividend Yield | 6.06% | — |
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.40, up 0.42% with a bullish technical signal from moving averages. The company maintains strong profitability with a 73.18% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights Pfizer's focus on AI drug discovery and a catalyst-rich pipeline in obesity and oncology for 2026, while analysts maintain a mixed consensus with 40% buy ratings.
Pfizer presents a balanced opportunity with stable cash flows and dividend payments, but faces headwinds from patent cliffs and declining net income margins. The stock trades near analyst consensus targets with moderate upside potential, though execution risks in pipeline development and competitive pressures warrant caution for growth-oriented investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →